Division of Infectious Diseases, Vagelos College of Physicians and Surgeons, Columbia University, NewYork, New York.
Division of Infectious Diseases, Weill Cornell Medicine, New York, NY.
J Infect Dis. 2024 Mar 26;229(Supplement_2):S229-S233. doi: 10.1093/infdis/jiad492.
Clinical severity scores facilitate comparisons to understand risk factors for severe illness. For the 2022 multinational monkeypox clade IIb virus outbreak, we developed a 7-item Mpox Severity Scoring System (MPOX-SSS) with initial variables refined by data availability and parameter correlation. Application of MPOX-SSS to the first 200 patients diagnosed with mpox revealed higher scores in those treated with tecovirimat, presenting >3 days after symptom onset, and with CD4 counts <200 cells/mm3. For individuals evaluated repeatedly, serial scores were concordant with clinical observations. The pilot MPOX-SSS demonstrated good discrimination, distinguished change over time, and identified higher scores in expected groups.
临床严重程度评分有助于比较，以了解导致严重疾病的风险因素。针对 2022 年多国猴痘 IIb 病毒爆发，我们开发了一个 7 项的猴痘严重程度评分系统（MPOX-SSS），初始变量经过数据可用性和参数相关性的优化。在对 200 名确诊感染猴痘的患者进行应用后发现，接受特考韦瑞治疗、症状出现后超过 3 天、CD4 计数<200 个细胞/mm3 的患者的评分更高。对于反复评估的个体，连续评分与临床观察结果一致。该初步的 MPOX-SSS 显示出良好的判别能力、能区分随时间的变化，并识别出预期的高评分组。
